-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Ascentage Pharma's Olverembatinib And Lisaftoclax Demonstrate Strong Clinical Data Across Chronic Myeloid Leukemia, Ph+ ALL And CLL/SLL In Seventeen Updates At EHA2026 Congress

Benzinga·06/15/2026 06:46:53
Listen to the news

Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies